New combo therapy aims to save rectums from surgery
NCT ID NCT07527026
First seen Apr 16, 2026 · Last updated May 20, 2026 · Updated 6 times
Summary
This study tests whether adding the immunotherapy drug camrelizumab to standard chemoradiation can make rectal cancer disappear completely in more patients. About 44 adults with locally advanced rectal cancer will receive the combination before any surgery. The goal is to increase the chance of avoiding permanent colostomy and preserving the rectum.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.